Johnson & Johnson earnings top forecasts, shares jump, on new cancer drug boost

  • 📰 startelegram
  • ⏱ Reading Time:
  • 11 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 8%
  • Publisher: 63%

Portugal Notícia Notícia

Portugal Últimas Notícias,Portugal Manchetes

Johnson & Johnson's newly-structured business, which no longer includes a consumer healthcare unit, is seeing solid demand for its new cancer-focused treatments Carvykti and Tecvayli.

posted stronger-than-expected third quarter earnings Tuesday, while boosting its full-year profit forecast, thanks in part to solid gains for its new cancer treatments.

Pharmaceuticals sales were up 5.1% to $13.9 billion while Medtech sales jumped 10% to $7.46 billion. Consumer health sales were spun-off to Kenvue, the group's stand-alone entity, earlier this year.

Resumimos esta notícia para que você possa lê-la rapidamente. Se você se interessou pela notícia, pode ler o texto completo aqui. Consulte Mais informação:

 /  🏆 248. in PT
 

Obrigado pelo seu comentário. Seu comentário será publicado após ser revisado.

Portugal Últimas Notícias, Portugal Manchetes

Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.

Johnson & Johnson Reports Earnings Tuesday. What to ExpectAn update in August after the split leaves investors with fewer questions for Tuesday's results.
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »

Johnson & Johnson earnings: What to expectJohnson & Johnson is not expected to produce big surprises in its earnings release due Tuesday
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
Fonte: NBCLA - 🏆 319. / 59 Consulte Mais informação »

Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surgeIt marks J&J’s first quarterly results since the company completed the separation from its consumer health spinoff Kenvue in August.  
Fonte: NBCNewYork - 🏆 270. / 63 Consulte Mais informação »

Johnson & Johnson's stock climbs after company beats earnings estimates and raises profit guidanceJohnson & Johnson raised its full year EPS guidance and lifted the midpoint of its sales range
Fonte: MarketWatch - 🏆 3. / 97 Consulte Mais informação »